According to Fintel, HC Wainwright & Co. has reiterated its coverage of Nuvectis Pharma (NASDAQ:NVCT) with a Buy recommendation.
Analyst Price Forecast suggests a 49.14% upside.
As of August 31, 2023, the average one-year price target for Nuvectis Pharma is $20.91, with a low of $20.20 and a high of $22.05. This represents a 49.14% increase from the latest reported closing price of $14.02.
Check out the leaderboard of companies with the largest price target upside.
The projected annual revenue for Nuvectis Pharma is $0MM, while the projected annual non-GAAP EPS is -1.58.
There are 90 funds or institutions reporting positions in Nuvectis Pharma, an increase of 64 owners or 246.15% in the last quarter. The average portfolio weight of all funds dedicated to NVCT is 0.01%, an increase of 87.89%. Total shares owned by institutions increased by 157.61% to 1,303K shares in the last three months.
Vanguard Total Stock Market Index Fund Investor Shares holds 181K shares representing 1.05% ownership of the company, with no change in the last quarter. iShares Russell 2000 ETF holds 139K shares representing 0.81% ownership. Geode Capital Management holds 113K shares representing 0.65% ownership, which is an increase of 68.88% from its previous filing. Baldwin Brothers holds 90K shares representing 0.52% ownership, a decrease of 59.67% from its previous filing. Forbes J M & Co Llp holds 67K shares representing 0.39% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available, providing data that covers fundamentals, analyst reports, ownership data, fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and more. They also offer exclusive stock picks powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
